Lonza Group is a Swiss multinational manufacturing company for the pharmaceutical, biotechnology and nutrition sectors, headquartered in Basel, with major facilities in Europe, North America and South Asia.
| FactSnippet No. 1,461,072 |
15 Facts About Lonza Group
2.
Lonza Group was established under that name in the late 19th-century in Switzerland.
| FactSnippet No. 1,461,073 |
3.
Lonza Group provides product development services to the pharmaceutical and biologic industries, including custom manufacturing of biopharmaceuticals and detection systems and services for the bioscience sector.
| FactSnippet No. 1,461,074 |
4.
Lonza Group was founded in 1897 in the small Swiss town of Gampel, situated in the canton of Valais, taking its name from the nearby river.
| FactSnippet No. 1,461,075 |
5.
Competition from electric lighting reduced demand for calcium carbide and in 1915 Lonza Group started industrial production of calcium cyanamide which became popular as a cheap nitrogenous fertilisers, only to be supplanted by urea.
| FactSnippet No. 1,461,076 |
6.
In 1923, Lonza Group started to convert calcium carbide to metaldehyde via acetylene and acetaldehyde.
| FactSnippet No. 1,461,077 |
7.
At the start of WWII, Lonza Group was contracted by the Swiss government to produce synthetic fuel, which it did by converting acetaldehyde to paraldehyde, used as an additive in transport fuel.
| FactSnippet No. 1,461,078 |
8.
Ketene was initially used to make cellulose acetate for rayon manufacture, but after 1947 Lonza Group converted most of its ketene to diketene, which was then converted to a range of chemical precursors.
| FactSnippet No. 1,461,079 |
9.
Lonza Group is involved in the manufacturing of biologics with several pharmaceutical companies.
| FactSnippet No. 1,461,080 |
10.
Lonza Group entered into a partnership with Teva in 2009 to develop and manufacture biosimilars.
| FactSnippet No. 1,461,081 |
11.
In 2014, Lonza Group entered into an agreement with Bristol-Myers Squibb to manufacture two biologic drugs.
| FactSnippet No. 1,461,082 |
12.
In 2015, Lonza Group contracted with Alexion to construct a new facility dedicated to Alexion manufacturing.
| FactSnippet No. 1,461,083 |
13.
In May 2020, Moderna struck a manufacturing deal with Lonza Group to produce its COVID-19 vaccine active ingredient while expanding sterile production and fill-finish activities to 500 million doses starting in 2021.
| FactSnippet No. 1,461,084 |
14.
Lonza Group is responsible for the global production of two-thirds of the raw materials for the Moderna vaccine at combined U S and Swiss facilities.
| FactSnippet No. 1,461,085 |
15.
Lonza Group started to collaborate with Altimmune Inc for the development of a nasal COVID-19 vaccine.
| FactSnippet No. 1,461,086 |